ImmunityBio
IBRX
147 hedge funds and large institutions have $292M invested in ImmunityBio in 2023 Q4 according to their latest regulatory filings, with 30 funds opening new positions, 57 increasing their positions, 28 reducing their positions, and 13 closing their positions.
247% more capital invested
Capital invested by funds: $84.1M → $292M (+$208M)
183% more call options, than puts
Call options by funds: $14.5M | Put options by funds: $5.13M
131% more first-time investments, than exits
New positions opened: 30 | Existing positions closed: 13
104% more repeat investments, than reductions
Existing positions increased: 57 | Existing positions reduced: 28
12% more funds holding
Funds holding: 131 → 147 (+16)
1.24% more ownership
Funds ownership: 7.47% → 8.71% (+1.2%)
Top Buyers
| 1 |
State Street
Boston,
Massachusetts
|
+$21.2M |
| 2 |
Goldman Sachs
New York
|
+$2.67M |
| 3 |
Jane Street
New York
|
+$2.58M |
| 4 |
Morgan Stanley
New York
|
+$2.52M |
| 5 |
Rafferty Asset Management
New York
|
+$2.32M |
Top Sellers
| 1 |
AC
Armistice Capital
New York
|
-$5.87M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$4.23M |
| 3 |
Group One Trading
Chicago,
Illinois
|
-$1.4M |
| 4 |
National Bank of Canada
Montreal,
Quebec, Canada
|
-$1.07M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$852K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
151
Verition Fund Management
Greenwich,
Connecticut
| – | -$143K | -84,770 | Closed |
|
152
Point72 Asset Management
Stamford,
Connecticut
| – | -$26.2K | -15,500 | Closed |
|
|
WG
153
Winton Group
London,
United Kingdom
| – | -$26.1K | -15,438 | Closed |
|
|
EGM
154
Engineers Gate Manager
New York
| – | -$23K | -13,632 | Closed |
|
|
MAWA
155
Moss Adams Wealth Advisors
Seattle,
Washington
| – | -$20.9K | -12,341 | Closed |
|
|
SPC
156
Sigma Planning Corp
Ann Arbor,
Michigan
| – | -$18.7K | -11,050 | Closed |
|
157
US Bancorp
Minneapolis,
Minnesota
| – | -$2.89K | -1,710 | Closed |
|
|
PA
158
Parallel Advisors
San Francisco,
California
| – | -$1.69K | -1,000 | Closed |
|
|
CG
159
Cutler Group
San Francisco,
California
| – | -$1.77K | -564 | -87% |
|
|
C
160
Covestor
London,
United Kingdom
| – | +$129 | +41 | +111% |
|
IBRX Hedge Fund Activity: Q4 2023 in Review
147 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in ImmunityBio (IBRX) for Q4 2023, worth a combined $292M — up 247% from $84.1M a quarter earlier.
Buyers outnumbered sellers: 30 funds opened new IBRX positions and 13 closed out — a net gain of 17 holders — while 57 added to existing stakes and 28 trimmed.
The largest buyer was State Street, adding an estimated $21.2M. The largest seller was Armistice Capital, exiting entirely with an estimated $5.87M sold.
- 147 institutional investors held ImmunityBio (IBRX) as of Q4 2023, up from 131 in Q3 2023.
- Funds reported $292M of ImmunityBio stock for Q4 2023, up 247% quarter-over-quarter.
- 30 funds opened new ImmunityBio positions in Q4 2023 and 13 closed out, a net change of +17 holders.
- The largest ImmunityBio buyer in Q4 2023 was State Street, an estimated $21.2M added.
- The largest ImmunityBio seller in Q4 2023 was Armistice Capital, an estimated $5.87M sold.
Based on aggregated 13F filings for Q4 2023.